![]() |
市場調查報告書
商品編碼
1828106
2025年角膜植入全球市場報告Corneal Implants Global Market Report 2025 |
近年來,角膜植入市場呈現強勁成長勢頭,市場規模從2024年的13.4億美元增至2025年的14.2億美元,複合年成長率為5.5%。預測期內的成長可歸因於先進的手術技術、早期生物材料的創新、角膜移植的興起、人們對眼科疾病認知的不斷提高以及先鋒外科醫生的湧現。
預計未來幾年角膜植入市場規模將強勁成長,2029年將達到18.7億美元,複合年成長率為7.2%。預測期內的成長歸因於個人化醫療方法的推進、可及性和認知度的提高、創新生物材料的開發、屈光矯正手術的增加以及人口老化。預測期內的主要趨勢包括微創技術的興起、監管支持和核准、認知度和可及性的提高、生物材料創新以及屈光矯正手術的增加。
角膜植入屈光矯正手術是一種外科介入手段,旨在透過植入人工或假體裝置來替換或強化受損或患病的角膜。該手術旨在解決視力障礙並減輕相關疼痛。
角膜植入主要分為兩類:人工角膜植入和人類角膜植入。人工角膜植入是專門設計用於替代受損或患病角膜的醫療設備。角膜植入採用多種技術製成,包括內皮角膜移植和穿透性角膜移植。這些手術用途廣泛,包括治療圓錐角膜、福克斯角膜營養不良、感染性角膜炎和角膜潰瘍等疾病。角膜移植手術通常在醫院或眼科中心等醫療機構進行。
2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對影像處理設備、手術用不銹鋼和一次性塑膠等進口零件產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰使情況更加複雜,因為由於關稅而更換供應商通常需要醫療設備重新認證,導致市場進入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司(The Business Research Company)新報告系列的一部分,該系列提供角膜植入市場統計數據,包括全球市場規模、區域佔有率、競爭對手的角膜植入市場佔有率、詳細的角膜植入細分市場、市場趨勢和商業機會,以及您在角膜植入行業取得成功所需的數據。本角膜植入市場研究報告對該行業的現狀和未來趨勢進行了詳細分析,為您提供所需的一切觀點。
未來五年7.2%的預測成長率,較我們先前對該市場的預測略有下降0.2%。下降主要源自於美國與其他國家之間關稅的影響。這可能會透過對來自英國和英國等主要地區的生物相容性水凝膠材料和飛秒雷射切割系統徵收關稅直接影響美國,並可能導致視力恢復延遲和圓錐角膜治療上升。此外,透過互惠關稅以及貿易緊張局勢和限制措施升級對全球經濟和貿易的負面影響,這種影響也將更為廣泛地顯現。
預計角膜疾病盛行率將在未來幾年推動角膜植入市場的擴張。角膜疾病包括多種影響角膜(眼睛前部透明的圓頂狀結構)的疾病,會導致視力障礙和不適。角膜疾病盛行率的不斷上升推動了對角膜植入的需求,角膜植入物提供了多種解決方案,包括治療角膜異常、改善角膜完整性、緩解症狀和改善視力。例如,根據美國疾病管制中心 (CDC) 於 2022 年 12 月發布的數據,美國40 歲及以上人口中白內障(一種角膜疾病)的盛行率估計為 2,050 萬,約佔該年齡層人口的 17.2%。此外,預計到 2028 年這一數字將超過 3,000 萬。因此,角膜疾病的快速增加是角膜植入市場成長的主要驅動力。
預計醫療保健支出的增加也將在短期內推動角膜植入市場的擴張。醫療保健支出是指在特定時期和地區內分配給醫療保健產品和服務的總資源(包括財政資源)。醫療保健投資的增加將推動眼科領域採用先進技術和手術技術,包括角膜植入的使用。例如,根據美國醫療保險和醫療補助服務中心於 2022 年 3 月發布的《2021-2030 年國家衛生支出 (NHE) 報告》,預計成長率表明,2021 年至 2030 年期間,國家醫療保健支出將以年均 5.1% 的速度成長,總額約為 6.8 兆美元。此外,預計 2021 年至 2030 年間,醫療保險支出將以每年 7.2% 的速度成長,醫療補助支出將以每年 5.6% 的速度成長。因此,醫療保健支出的增加是推動角膜植入市場成長的關鍵因素。
角膜植入市場的主要企業正致力於開發創新的角膜輪廓解決方案,以增強視力矯正和治療各種角膜疾病。這些解決方案包括先進的手術技術和設備,旨在再形成角膜以改善視力並解決屈光不正和角膜疾病。例如,2024 年 6 月,專注於消除角膜失明的美國醫療設備開發商 CorneaGen 推出了角膜組織添加角膜移植術 (CTAK)。這種創新解決方案描述了一種針對角膜病眼的高效角膜輪廓修復方法。 CTAK 手術將供體角膜組織添加到現有角膜,而不是完全取代它。該方法旨在恢復角膜的自然輪廓,增強光學清晰度並改善患者的整體視覺效果。
角膜植入市場的主要企業正在建立策略夥伴關係關係,以推進和推出用於眼科應用的組織衍生植入。策略夥伴關係關係是指各公司利用彼此的優勢和資源,實現互利共贏。例如,2022年7月,德國醫療技術公司卡爾蔡司醫療科技公司 (Carl Zeiss Meditec AG) 與美國再生醫學公司 Precise Bio 合作,專注於開發和開發用於移植的人工角膜組織。該舉措專門針對需要內皮角膜移植和天然雀斑移植的患者,用於治療圓錐角膜和視力矯正等疾病。此次夥伴關係充分利用了蔡司在眼科領域的全球領導地位以及 Precise 創新的 4D 生物製造平台技術。
2023年1月,美國製藥保健公司Viatris Inc.分別以4.15億美元和2.8億美元收購了Oyster Point Pharma和Family Life Sciences。 Viatris Inc.旨在透過這些收購擴大其商業性影響力和產品組合,將自身定位為眼科護理領域的全球領導者,並滿足眼科疾病患者和眼科護理專業人士尚未滿足的需求。 Oyster Point Pharma是一家美國生物製藥公司,專門從事眼科疾病新型治療方法的識別、開發和商業化;而Family Life Sciences是一家印度藥物開發平台,專注於眼科領域。
角膜植入市場的主要企業包括佛羅裡達獅子眼庫公司、愛爾康公司、Aurolab Aravind 眼科護理系統、CorneaGen、AJL Ophthalmic SA、DIOPTEX Co.Ltd.、KeraMed Inc.、阿拉巴馬眼庫公司、CorNeat Vision Ltd.、MediPhacos、EyeYon Science Ltd, Visiono LLC、麻薩諸塞州眼耳醫院、Carl Zeiss Meditec AG、Precise Bio Inc、博士倫公司、強生視力、雅培醫療光學公司、STAAR Surgical Company、蔡司集團、豪雅公司、Rayner Intraocular Lenses Limited、HumanOptics AG、Morcher GmbH、Lenstec Inc、Ocular Systems Inc、Moria、Optics AG、Morcher GmbH、Lenstec Inc.、Ocular Inc、MoriaCI、Corcs AG、Clmt、Corphone Systems Inc.、Ocular
2024年,北美是角膜植入市場最大的地區。預計預測期內,亞太地區將成為全球角膜植入市場成長最快的地區。角膜植入市場報告涵蓋亞太地區、西歐、東歐、北美、南美以及中東和非洲。
角膜植入市場報告涵蓋的國家:澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、加拿大、義大利、西班牙
角膜植入市場包括提供角膜移植服務的營業單位產生的收益,例如深層前板層角膜移植術 (DALK) 和無內皮細胞後彈力膜角膜移植術 (DWEK)。市場規模包括服務提供者銷售或包含在其服務產品中的相關商品的價值。僅包括企業之間交易或銷售給最終消費者的商品和服務。
Corneal implants involve a surgical intervention aimed at either replacing or enhancing a damaged or diseased cornea through the integration of an artificial or prosthetic device. This procedure is carried out to address visual impairments and alleviate associated pain.
The two primary categories of corneal implants are artificial corneal implants and human corneal implants. Artificial corneal implants are medical devices specifically designed to substitute a damaged or diseased cornea. Various techniques, such as endothelial keratoplasty and penetrating keratoplasty, are employed for corneal implants. These procedures serve diverse applications, including addressing conditions such as keratoconus, Fuchs dystrophy, infectious keratitis, corneal ulcers, among others. The implementation of corneal implant procedures typically takes place in medical facilities such as hospitals and ophthalmic centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The corneal implants market research report is one of a series of new reports from The Business Research Company that provides corneal implants market statistics, including corneal implants industry global market size, regional shares, competitors with a corneal implants market share, detailed corneal implants market segments, market trends and opportunities, and any further data you may need to thrive in the corneal implants industry. This corneal implant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The corneal implants market size has grown strongly in recent years. It will grow from $1.34 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to pioneering surgical techniques, early biomaterial innovation, emergence of keratoplasty, rising awareness of eye disorders, pioneering surgeons' contributions.
The corneal implants market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to personalized medicine approaches, greater accessibility and awareness, innovative biomaterials development, rise in refractive surgeries, growing aging population. Major trends in the forecast period include emergence of minimally invasive techniques, regulatory support and approvals, increased awareness and accessibility, innovation in biomaterials, rise in refractive surgery.
The forecast of 7.2% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on biocompatible hydrogel materials and femtosecond laser-cutting systems, sourced from key regions such as the UK and Mexico, which could lead to vision restoration delays and higher costs for keratoconus treatments.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in the prevalence of corneal disorders is poised to drive the expansion of the corneal implant market in the coming years. Corneal disorders encompass a range of medical conditions affecting the cornea, the clear, dome-shaped front surface of the eye, leading to visual impairment and discomfort. The growing incidence of corneal disorders has resulted in an increased demand for corneal implants, offering diverse solutions for treating corneal abnormalities, enhancing corneal integrity, alleviating symptoms, and improving vision. As an example, data from the Center for Disease Control (CDC) in December 2022 revealed that in the United States, the prevalence of cataracts (a corneal disorder) among individuals aged over 40 is estimated at 20.5 million, constituting approximately 17.2% of the population in that age group. Moreover, this figure is projected to surpass 30 million by the year 2028. Consequently, the upsurge in corneal disorders is a key driver for the growth of the corneal implant market.
The escalating healthcare expenditure is also expected to propel the expansion of the corneal implants market in the foreseeable future. Healthcare expenditure denotes the total resources, including financial resources, allocated to healthcare goods and services within a specific period and geographical area. The increased investment in healthcare facilitates the adoption of advanced technologies and surgical techniques within the ophthalmology field, including the utilization of corneal implants. For instance, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, the projected growth suggests an average annual increase of 5.1% in national health spending between 2021 and 2030, reaching a total of nearly $6.8 trillion. Furthermore, it is anticipated that from 2021 to 2030, Medicare spending will rise at a 7.2% annual pace, while Medicaid spending will increase at a 5.6% annual rate. Hence, the escalating healthcare expenditure is a significant factor propelling the growth of the corneal implants market.
Major companies in the corneal implants market are concentrating on developing innovative corneal contouring solutions to enhance vision correction and treat various corneal disorders. These solutions involve advanced surgical techniques and devices aimed at reshaping the cornea to improve vision and address refractive errors or corneal diseases. For instance, in June 2024, CorneaGen, a US-based developer of medical devices focused on eliminating corneal blindness, launched the Corneal Tissue Addition for Keratoplasty (CTAK). This innovative solution offers a highly effective approach to corneal contouring for keratoconic eyes. The CTAK technique involves adding donor corneal tissue to the existing cornea instead of completely replacing it. This method aims to restore the natural contour of the cornea, thereby enhancing optical clarity and improving overall visual outcomes for patients.
Major players in the corneal implants market are embracing strategic partnerships to advance and introduce tissue-derived implants for ophthalmological applications. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit and success. For instance, in July 2022, Carl Zeiss Meditec AG, a German medical technology company, collaborated with Precise Bio, a US regenerative medicine company, focusing on the development and market launch of engineered corneal tissue for transplants. This initiative specifically caters to patients in need of endothelial keratoplasty and natural lenticule transplants for conditions such as keratoconus and vision correction. The partnership leverages ZEISS' global leadership in ophthalmology and Precise's innovative 4D bio-fabrication platform technology.
In January 2023, Viatris Inc., a US-based pharmaceutical and healthcare corporation, completed the acquisitions of Oyster Point Pharma and Family Life Sciences for $415 million and $280 million, respectively. Through these acquisitions, Viatris Inc. aims to expand its commercial presence and portfolio, positioning itself as a global leader in eye care, and addressing the unmet needs of patients with ophthalmic diseases and eye care professionals. Oyster Point Pharma, a US biopharmaceutical company, specializes in identifying, developing, and marketing novel treatments for eye diseases, while Family Life Sciences, an Indian drug development platform, specializes in ophthalmology.
Major companies operating in the corneal implants market include Florida Lions Eye Bank Inc., Alcon Inc., Aurolab Aravind Eye Care System, CorneaGen, AJL Ophthalmic SA, DIOPTEX Co. Ltd., KeraMed Inc., Alabama Eye Bank Inc., CorNeat Vision Ltd., MediPhacos, EyeYon Medical Ltd., Linkocare Life Sciences AB, Price Vision Group, Cornea Biosciences LLC, Massachusetts Eye and Ear Infirmary, Carl Zeiss Meditec AG, Precise Bio Inc., Bausch & Lomb Incorporated, Johnson & Johnson Vision, Abbott Medical Optics Inc., STAAR Surgical Company, ZEISS Group, Hoya Corporation, Rayner Intraocular Lenses Limited, HumanOptics AG, Morcher GmbH, Lenstec Inc., Ocular Systems Inc., Moria SA, DORC International BV, Coroneo Pty Ltd, FCI Ophthalmics Inc.
North America was the largest region in the cornea implants market in 2024. Asia Pacific is expected to be the fastest-growing region in the global cornea implants market during the forecast period. The regions covered in the corneal implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the corneal implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The corneal implants market includes revenues earned by entities by providing corneal implantation services, including deep anterior lamellar keratoplasty (DALK) and Descemet rhexis without endothelial keratoplasty (DWEK). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Corneal Implants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on corneal implants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for corneal implants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The corneal implants market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.